today announced an oral presentation at the upcoming 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference being held March 16-19 in Dallas. “The oral presentation at this ...
will present topline del-zota data from Avidity's Phase 1/2 EXPLORE44 trial for people living with Duchenne Muscular Dystrophy amenable to exon 44 skipping (DMD44). March 16-18, 2025: 6:00 p.m ...
Oral Presentation: Title: First-in-human Phase 1 study of orally administered SAT-3247 in healthy volunteers and adult participants with Duchenne Muscular Dystrophy (DMD) Date: Wednesday ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback